RT Journal Article
SR Electronic
T1 Multimodal Large Language Models are Generalist Medical Image Interpreters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.21.23300146
DO 10.1101/2023.12.21.23300146
A1 Han, Tianyu
A1 Adams, Lisa C.
A1 Nebelung, Sven
A1 Kather, Jakob Nikolas
A1 Bressem, Keno K.
A1 Truhn, Daniel
YR 2023
UL http://medrxiv.org/content/early/2023/12/22/2023.12.21.23300146.abstract
AB Advanced multimodal large language models (LLM), such as GPT-4V(ision) and Gemini Ultra, have shown promising results in the diagnosis of complex pathological conditions. This raises questions about their knowledge base: Do these models deeply understand medical cases, including images, or do they simply recognize superficial patterns from extensive pre-training? We aimed to determine whether LLMs can develop useable internal representations of images, and if these representations improve the classification of medical images. We rigorously tested the performance of the open-source Flamingo-80B model, which is not specifically tailored for medical tasks, against traditional pre-training methods. The tests covered eight distinct image classification tasks in pathology, dermatology, ophthalmology, and radiology, using CLIP, Flamingo-80B, and 9B multimodal models. These tasks ranged from tissue and nuclear classification in histopathology to lesion detection in dermatology and disease grading in radiology. We systematically evaluated the model’s internal image representations to determine their relevance and usefulness in medical diagnosis. Our analysis showed that the internal representation of these images in the largest model, Flamingo-80B, was more accurate in classifying medical images than in all other methods. These results held even when the number of samples available for training was small. Our results show that multimodal LLMs acquire structured knowledge in medical domains. This suggests that these models are evolving from mere pattern recognition tools into entities with broader medical generalist capabilities. This evolution underscores the potential for these models to make contributions to medical diagnosis and research, although it is important to continue to evaluate their capabilities and limitations in real-world medical settings.Competing Interest StatementD.T. holds shares in StratifAI GmbH and reports speaker fees from Bayer, Germany. K.K.B. reports speaker fees from Canon Medical Systems Corporation and GE HealthCare. No other disclosures are reported. Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes